21 January 2019
Visiongain has launched a new pharma report Global Cancer Immunotherapy Market Report : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics.
Immunotherapeutics and targeted therapies are emerging as promising treatment options for various cancer types. In the biological cancer drug category, monoclonal antibodies (mAbs) have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity.
The lead analyst of the report commented "The cancer immunotherapy market remains attractive, as it is a large and growing clinical area with growing incidence of cancer cases, globally. Significant unmet need exists in the cancer market due to the rising need for more compelling clinical evidences and improved patient convenience.
In addition, increased medical education to improve clinical practice, improved care coordination between therapies and sites of care, and enhanced decision tools and practice guidelines are expected to drive future trends and innovations."
Leading companies featured in the report include Adaxic Inc., AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Eli Lilly and Co., Medtronic Plc, Merck & Co., Inc. (Merck), Novartis, Pfizer, Roche
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
In clinical trials relating to COVID-19, COVID-19 biobanks will play an important role. These biobanks will play an instrumental role in future scientific studies on the emerging coronavirus (COVID-19) pandemic facing the world.
23 October 2020
Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.
19 October 2020
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.
12 October 2020
We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.